A detailed history of Acadian Asset Management LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 2,029,721 shares of EXEL stock, worth $71.6 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
2,029,721
Previous 457,853 343.31%
Holding current value
$71.6 Million
Previous $10.3 Million 412.07%
% of portfolio
0.16%
Previous 0.03%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.96 - $27.6 $34.5 Million - $43.4 Million
1,571,868 Added 343.31%
2,029,721 $52.6 Million
Q2 2024

Aug 06, 2024

SELL
$20.34 - $23.73 $15.5 Million - $18.1 Million
-760,661 Reduced 62.43%
457,853 $10.3 Million
Q1 2024

May 10, 2024

SELL
$20.17 - $23.93 $11.2 Million - $13.2 Million
-553,663 Reduced 31.24%
1,218,514 $28.9 Million
Q4 2023

Feb 13, 2024

SELL
$19.25 - $24.13 $3.57 Million - $4.48 Million
-185,671 Reduced 9.48%
1,772,177 $42.5 Million
Q3 2023

Nov 13, 2023

BUY
$19.04 - $22.74 $34 Million - $40.6 Million
1,786,687 Added 1043.86%
1,957,848 $42.8 Million
Q2 2023

Aug 07, 2023

BUY
$18.17 - $20.48 $2.67 Million - $3 Million
146,720 Added 600.3%
171,161 $3.27 Million
Q1 2023

May 11, 2023

SELL
$16.3 - $19.41 $2.15 Million - $2.56 Million
-132,148 Reduced 84.39%
24,441 $474,000
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $320,248 - $372,267
21,407 Added 15.84%
156,589 $2.51 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $1.06 Million - $1.51 Million
67,835 Added 100.72%
135,182 $2.12 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $1.06 Million - $1.51 Million
67,835 Added 100.72%
135,182 $2.12 Million
Q2 2022

Aug 09, 2022

BUY
$17.44 - $23.16 $704,942 - $936,150
40,421 Added 150.12%
67,347 $1.4 Million
Q1 2022

May 12, 2022

SELL
$17.03 - $22.67 $97,173 - $129,355
-5,706 Reduced 17.49%
26,926 $610,000
Q4 2021

Feb 10, 2022

SELL
$15.84 - $21.88 $111,038 - $153,378
-7,010 Reduced 17.68%
32,632 $596,000
Q3 2021

Nov 12, 2021

BUY
$16.3 - $21.14 $352,569 - $457,258
21,630 Added 120.09%
39,642 $836,000
Q2 2021

Aug 11, 2021

SELL
$17.95 - $25.56 $1.92 Million - $2.73 Million
-106,768 Reduced 85.56%
18,012 $328,000
Q1 2021

May 11, 2021

SELL
$20.53 - $25.22 $13 Million - $16 Million
-635,094 Reduced 83.58%
124,780 $2.82 Million
Q4 2020

Feb 11, 2021

BUY
$18.39 - $24.8 $983,037 - $1.33 Million
53,455 Added 7.57%
759,874 $15.3 Million
Q3 2020

Nov 09, 2020

SELL
$20.67 - $26.94 $772,582 - $1.01 Million
-37,377 Reduced 5.03%
706,419 $17.3 Million
Q2 2020

Aug 12, 2020

BUY
$16.46 - $27.42 $112,849 - $187,991
6,856 Added 0.93%
743,796 $17.7 Million
Q1 2020

May 11, 2020

BUY
$14.46 - $21.8 $3.09 Million - $4.66 Million
213,708 Added 40.84%
736,940 $12.7 Million
Q4 2019

Feb 06, 2020

BUY
$15.15 - $18.89 $4.49 Million - $5.6 Million
296,696 Added 130.97%
523,232 $9.22 Million
Q3 2019

Nov 07, 2019

BUY
$17.68 - $22.65 $3.63 Million - $4.65 Million
205,091 Added 956.36%
226,536 $4.01 Million
Q2 2019

Aug 08, 2019

SELL
$18.93 - $24.75 $281,981 - $368,676
-14,896 Reduced 40.99%
21,445 $458,000
Q1 2019

May 09, 2019

BUY
$19.6 - $24.76 $468,420 - $591,739
23,899 Added 192.08%
36,341 $866,000
Q4 2018

Feb 07, 2019

BUY
$13.65 - $21.8 $104,463 - $166,835
7,653 Added 159.8%
12,442 $246,000
Q3 2018

Oct 30, 2018

BUY
$15.87 - $22.4 $7,093 - $10,012
447 Added 10.29%
4,789 $85,000
Q2 2018

Jul 24, 2018

SELL
$18.56 - $22.45 $61,210 - $74,040
-3,298 Reduced 43.17%
4,342 $93,000
Q1 2018

Apr 12, 2018

SELL
$22.15 - $31.89 $6.12 Million - $8.82 Million
-276,497 Reduced 97.31%
7,640 $169,000
Q4 2017

Jan 18, 2018

SELL
$24.23 - $30.93 $23 Million - $29.4 Million
-949,347 Reduced 76.96%
284,137 $8.64 Million
Q3 2017

Oct 13, 2017

BUY
$23.35 - $29.24 $28.8 Million - $36.1 Million
1,233,484
1,233,484 $29.9 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.3B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.